Increasing evidence suggests that an overactive endocannabinoid system (ECS) may contribute to the development of diabetes by promoting energy intake and storage, impairing both glucose and lipid metabolism, by exerting pro-apoptotic effects in pancreatic beta cells and by facilitating inflammation in pancreatic islets. Furthermore, hyperglycaemia associated with diabetes has also been implicated in triggering perturbations of the ECS amplifying the pathological processes mentioned above, eventually culminating in a vicious circle. Compelling evidence from preclinical studies indicates that the ECS also influences diabetes-induced oxidative stress, inflammation, fibrosis and subsequent tissue injury in target organs for diabetic complications. In this review, we provide an update on the contribution of the ECS to the pathogenesis of diabetes and diabetic microvascular (retinopathy, nephropathy and neuropathy) and cardiovascular complications. The therapeutic potential of targeting the ECS is also discussed.

Role of the endocannabinoid system in diabetes and diabetic complications

GRUDEN, Gabriella
First
;
BARUTTA, FEDERICA;
2016-01-01

Abstract

Increasing evidence suggests that an overactive endocannabinoid system (ECS) may contribute to the development of diabetes by promoting energy intake and storage, impairing both glucose and lipid metabolism, by exerting pro-apoptotic effects in pancreatic beta cells and by facilitating inflammation in pancreatic islets. Furthermore, hyperglycaemia associated with diabetes has also been implicated in triggering perturbations of the ECS amplifying the pathological processes mentioned above, eventually culminating in a vicious circle. Compelling evidence from preclinical studies indicates that the ECS also influences diabetes-induced oxidative stress, inflammation, fibrosis and subsequent tissue injury in target organs for diabetic complications. In this review, we provide an update on the contribution of the ECS to the pathogenesis of diabetes and diabetic microvascular (retinopathy, nephropathy and neuropathy) and cardiovascular complications. The therapeutic potential of targeting the ECS is also discussed.
2016
173
7
1116
1127
http://onlinelibrary.wiley.com/doi/10.1111/bph.v173.7/issuetoc
Gruden, G; Barutta, F; Kunos, G; Pacher, P2.
File in questo prodotto:
File Dimensione Formato  
s1-ln1893803395844769-1939656818Hwf-1835386216IdV35906230018938033PDF_HI0001.pdf

Accesso aperto

Descrizione: preprint
Tipo di file: PREPRINT (PRIMA BOZZA)
Dimensione 845.49 kB
Formato Adobe PDF
845.49 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1617690
Citazioni
  • ???jsp.display-item.citation.pmc??? 65
  • Scopus 116
  • ???jsp.display-item.citation.isi??? 112
social impact